Breast Cancer

JUNE PROJECT UPDATE

Helen Grimsley, who is partly funded by Kent Cancer Trust,  has been working on the Triple Negative Breast Cancer project in order to gain a PhD, since September 2016. She gave a fascinating desciption of what has been achieved in her first year in June 2017. In particular, she talked about the way in which her work has been helped by the ready availability of the Resistant Cancer Cell Line that is kept at the University of Kent

To date, she has characterised a panel of 18 triple-negative breast cancer cell lines (3 parental cell lines, 15 drug-adapted sub-lines) for sensitivity to a panel of anti-cancer drugs. In addition, the University of Kent has acquired the whole exome sequencing data for these cell lines (i.e. they know the sequences of all genes in the genome of these cell lines).  These data will be used to identify potential markers of resistance formation to inform anti-cancer therapies. If the  changes that indicate resistance formation are known, the  resistance formation can be monitored more closely in patients and hence spare them from a therapy that has stopped working. This will become more and more relevant with the use of liquid biopsies (e.g. circulating tumour DNA and circulating tumour cells that can be obtained from patients’ blood and indicate changes in the cancer cells of a patient). In addition, the combination of the drug sensitivity data and the genetic information can be used to indicate effective next-line therapies.


Breast Cancer
Webpage icon Breast Cancer